Ibrutix 140 mg (Ibrutinib)

Description

Ibrutix 140 mg Ibrutinib is an anti-cancer medicine. It works by blocking an abnormal protein that signals cancer cells to multiply. Ibrucent Ibrutinib helps stop the spread of cancer cells.

 

FAQ about Ibrutix 140 mg Ibrutinib

 

Q: What are Ibrutix 140 mg Ibrutinib side effects?

Ibrutix has some side effects

• Difficulty having a bowel movement.
• heartburn or indigestion
• muscle stiffness or spasms
• small red or purple spots on the skin
• stomach discomfort, upset, or pain
• swelling or inflammation of the mouth

 

Q: What is the cost of Ibrutix ibrutinib?

In the US ibrutinib costs $484 per capsule/tablet regardless of the strength 140mg. source here 

In the UK the cost of a year’s course of ibrutinib treatment is £55,954.50 (excluding VAT) source here 

But you can get this medicine at an affordable price from us. for order contact us

 or find at MFC

 

Q: What is the drug ibrutinib used for?

Ibrutinib is a type of targeted cancer drug. It is a treatment for mantle cell lymphoma. Chronic lymphocytic leukemia

 

Q: What cancers does ibrutinib treat?

A drug used alone or with other drugs to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom macroglobulinemia (a type of non-Hodgkin lymphoma), mantle cell lymphoma, or marginal zone lymphoma.

 

Q: How quickly does ibrutinib work?

Ibrutinib is a very effective CLL drug and provides evidence of rapid patient benefit concerning symptoms improving, lymph nodes decreasing, and blood counts improving. For some, a very good partial or clinical complete response can emerge clinically within 3-6 months

 

Dosage & Administration

MCL: 560 mg taken orally once daily (four 140 mg capsules once daily)
CLL and WM: 420 mg taken orally once daily (three 140 mg capsules once daily)
Capsules should be taken orally with a glass of water. The capsules should not be opened, broken, or chewed

 

Use in Pregnancy & Lactation

Pregnancy Category D
Based on animal data, Ibrutinib can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
It is not known whether Ibrutinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Ibrutinib, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use
The safety and effectiveness of Ibrutinib in pediatric patients have not been established.

Geriatric Use
No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects. No overall differences in effectiveness were observed between these patients and younger patients. Cardiac adverse events (atrial fibrillation and hypertension), infections (pneumonia, urinary tract infection, and cellulitis), and gastrointestinal events (diarrhea and dehydration) occurred more frequently among elderly patients.